InventisBio Co Ltd
688382
Company Profile
Business description
InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.
Contact
No. 4, Lane 67, Li Bing Road
Room 210
Pilot Free Trade Zone
Shanghai201203
CHNT: +86 2150778527
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
221
Stocks News & Analysis
video
What does the RBA rate cut mean for investors?
Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.
stocks
Insights from reporting season: So far, so good
We’ve upgraded our fair value estimate for 29 companies, or 40% of those that have reported thus far.
stocks
3 cheap ASX stocks owned by top rated funds
Our analysts think these companies are undervalued and their shares appear to have the stamp of approval from highly rated managers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,570.90 | 30.80 | -0.36% |
| CAC 40 | 8,154.51 | 31.93 | 0.39% |
| DAX 40 | 22,287.56 | 27.09 | -0.12% |
| Dow JONES (US) | 43,428.02 | 748.63 | -1.69% |
| FTSE 100 | 8,659.37 | 3.60 | -0.04% |
| HKSE | 23,477.92 | 900.94 | 3.99% |
| NASDAQ | 19,524.01 | 438.36 | -2.20% |
| Nikkei 225 | 38,776.94 | 98.90 | 0.26% |
| NZX 50 Index | 12,752.58 | 127.78 | -0.99% |
| S&P 500 | 6,013.13 | 104.39 | -1.71% |
| S&P/ASX 200 | 8,296.20 | 26.60 | -0.32% |
| SSE Composite Index | 3,379.11 | 28.33 | 0.85% |